Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib in FGFR2-amplified gastric cancer
NCT06206278Phase 2Terminated
- Sponsor
- LianBio
- Start
- Oct 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of infigratinib in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by LianBio. Started Oct 2023; status: terminated.
02
Drugs
infigratinib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06206278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06206278.